ESMO Insights | Professor Barbara Pistilli: Updated VIKTORIA-1 Results Show Sustained Survival Benefit and Improved Safety with Gedatolisib-Based Combinations in PIK3CA-Mutant Advanced Breast Cancer
At the 2026 ESMO Congress, Professor Barbara Pistilli of Gustave Roussy Cancer Center, France, presented updated results from VIKTORIA-1 Study 2 in patients with PIK3CA-mutant disease. The study showed that both the gedatolisib triplet combination (gedatolisib + palbociclib + fulvestrant) and the doublet combination (gedatolisib + fulvestrant) significantly improved progression-free survival (PFS) compared with alpelisib plus fulvestrant, regardless of whether patients had visceral or liver metastases. Based on these findings, Oncology Frontier interviewed Professor Barbara Pistilli at the congress to discuss the subgroup analyses, safety data, and clinical implications of the study.







